iTeos Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
iTeos Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • iTeos Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$48.8M, a 12.8% decline year-over-year.
  • iTeos Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$150M, a 61% decline year-over-year.
  • iTeos Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$151M, a 220% decline from 2022.
  • iTeos Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $126M, a 48.4% decline from 2021.
  • iTeos Therapeutics, Inc. annual Operating Income (Loss) for 2021 was $245M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$151M -$277M -220% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 $126M -$119M -48.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 $245M +$290M Jan 1, 2021 Dec 31, 2021 10-K 2024-03-06
2020 -$45.2M -$17.2M -61.3% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-23
2019 -$28M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.